Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
10.5 MG budesonide effervescent tablet FOR orodispersible USE1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
21 food elimination diet----1件: 98 💬
31 food elimination diet therapy----1件: 98 💬
41 MG budesonide effervescent tablet FOR orodispersible USE1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
51MG budesonide effervescent tablet FOR orodispersible USE1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
62MG budesonide effervescent tablet FOR orodispersible USE1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
74 food elimination diet----1件: 98 💬
85 MG montelukast1件: Montelukast2件: Montelukast sodium ,
Montelukast 💬 		1件: CYSLTR1 💬 2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬1件: 98 💬
96 food elimination diet therapy----1件: 98 💬
10AK002----1件: 98 💬
11Alpha-proteinase inhibitor----1件: 98 💬
12AMG 1571件: Tezepelumab1件: Tezepelumab 💬 1件: TSLP 💬 2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬1件: 98 💬
13AMG157----1件: 98 💬
14Antigen (wheat base SOY sauce) spray----1件: 98 💬
15APD334----5件: 93, 96, 97, 98, 269 💬
16APT-1011----1件: 98 💬
17APT-1011 - 3 MG----1件: 98 💬
18APT-1011 3 MG HS----1件: 98 💬
19AQ280----1件: 98 💬
20AR401959 L-arginine----3件: 96, 97, 98 💬
21Assessment OF medication compliance----1件: 98 💬
22Baked milk----1件: 98 💬
23Barium esophagram1件: Barium---1件: 98 💬
24Barzolvolimab1件: Barzolvolimab1件: Barzolvolimab 💬 1件: KIT 💬 11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬1件: 98 💬
25Beclomethasone dipropionate1件: Beclomethasone dipropionate3件: Beclomethasone dipropionate ,
Beclometasone ,
Beclomethasone dipropionate monohydrate 💬 		1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
26Benralizumab1件: Benralizumab1件: Benralizumab 💬 1件: IL5RA 💬 4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬5件: 44, 45, 98, 162, 299 💬
27Bethanechol1件: Bethanechol1件: Bethanechol chloride 💬 5件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬 		14件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬1件: 98 💬
28Blood sampling----9件: 13, 17, 46, 49, 51, 96, 98, 106, 162 💬
29Bone mineral density (dexa) scan----1件: 98 💬
30BT-11 high----1件: 98 💬
31BT-11 LOW----1件: 98 💬
32Budesonide1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬7件: 66, 93, 94, 95, 96, 97, 98 💬
33Budesonide 0.5 MG compresse orodispersibili1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
34Budesonide 0.5 MG orodispersible tablets1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
35Budesonide 0.5MG orodispersible tablet twice daily1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
36Budesonide 1 MG compresse orodispersibili1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
37Budesonide 1 MG orodispersible tablets1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
38Budesonide 1MG orodispersible tablet twice daily1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
39Budesonide [0.4MG/ML] viscous suspension1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
40Budesonide GEL1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
41Budesonide oral suspension1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
42Budesonide plus prevacid1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
43Buet 0.5 MG----1件: 98 💬
44Buet 1 MG----1件: 98 💬
45Buet 1MG----1件: 98 💬
46Buet 2MG----1件: 98 💬
47BUL 0.5 MG----1件: 98 💬
48BUL 1 MG----1件: 98 💬
49BUU 0.4MG/ML----1件: 98 💬
50CALY-0021件: CALY-002---1件: 98 💬
51CC-93538----1件: 98 💬
52CDX-0159----1件: 98 💬
53Cendakimab1件: Cendakimab1件: Cendakimab 💬 1件: IL13 💬 8件: Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation 💬1件: 98 💬
54Citalopram1件: Citalopram2件: Citalopram hydrobromide ,
Citalopram 💬 		1件: SLC6A4 💬 3件: Neuroactive ligand signaling, Serotonergic synapse, Synaptic vesicle cycle 💬5件: 6, 13, 46, 98, 127 💬
55Compressa effervescente 0,5 MG DI budesonide PER USO orodispersibile1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
56Compressa effervescente 1 MG DI budesonide PER USO orodispersibile1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
57Computerized tomography scan----1件: 98 💬
58Cortisol level1件: Hydrocortisone1件: Hydrocortisone 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
59CYP substrates----1件: 98 💬
60D-xylose----1件: 98 💬
61Dexlansoprazole1件: Dexlansoprazole2件: Dexlansoprazole ,
Dexlansoprazole sesquihydrate 💬 		2件: ATP4A,
ATP4B 💬 		3件: Collecting duct acid secretion, Gastric acid secretion, Oxidative phosphorylation 💬1件: 98 💬
62Dose----1件: 98 💬
63Dupilumab1件: Dupilumab1件: Dupilumab 💬 1件: IL4R 💬 8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬5件: 51, 97, 98, 160, 162 💬
64Dupixent1件: Dupilumab1件: Dupilumab 💬 1件: IL4R 💬 8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬3件: 98, 160, 162 💬
65Elimination diet----1件: 98 💬
66Else nutrition formula----1件: 98 💬
67Endoscopy while ON study drug----1件: 98 💬
68Eosinophilic esophagitis (E0E) food introduction-2ND----1件: 98 💬
69Eosinophilic esophagitis (EOE) food introduction-1ST----1件: 98 💬
70Eosinophilic esophagitis (EOE) food introduction-3RD dose----1件: 98 💬
71EP-104IAR----1件: 98 💬
72ESO-101----1件: 98 💬
73Esomeprazole1件: Esomeprazole5件: Esomeprazole magnesium ,
Esomeprazole sodium ,
Esomeprazole ,
Esomeprazole strontium ,
Esomeprazole magnesium dihydrate 💬 		2件: ATP4A,
ATP4B 💬 		3件: Collecting duct acid secretion, Gastric acid secretion, Oxidative phosphorylation 💬9件: 6, 13, 46, 86, 98, 107, 113, 298, 299 💬
74Esophacap----1件: 98 💬
75Esophageal barium xray----1件: 98 💬
76Esophageal biopsies----1件: 98 💬
77Esophageal dilation----1件: 98 💬
78Esophagogastroduodenoscopy----1件: 98 💬
79Etrasimod1件: Etrasimod2件: Etrasimod ,
Etrasimod arginine 💬 		3件: S1PR1,
S1PR4,
S1PR5 💬 		4件: Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬3件: 96, 97, 98 💬
80Etrasimod L-arginine1件: Etrasimod2件: Etrasimod ,
Etrasimod arginine 💬 		3件: S1PR1,
S1PR4,
S1PR5 💬 		4件: Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬3件: 96, 97, 98 💬
81EUR-1100----1件: 98 💬
82Famotidine1件: Famotidine1件: Famotidine 💬 1件: HRH2 💬 4件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction 💬5件: 6, 46, 98, 145, 300 💬
83Fasenra1件: Benralizumab1件: Benralizumab 💬 1件: IL5RA 💬 4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬5件: 44, 45, 98, 162, 299 💬
84Florence 30 µG/ML----1件: 98 💬
85Florence 60 µG/ML----1件: 98 💬
86Florence 90 µG/ML----1件: 98 💬
87Flovent----1件: 98 💬
88Fluticasone1件: Fluticasone1件: Fluticasone 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬3件: 98, 228, 299 💬
89Fluticasone MDI1件: Fluticasone1件: Fluticasone 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
90Fluticasone propionate2件: Fluticasone,
Fluticasone propionate		2件: Fluticasone propionate ,
Fluticasone 💬 		1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬3件: 98, 228, 306 💬
91Fluticasone propionate, USP2件: Fluticasone,
Fluticasone propionate		2件: Fluticasone propionate ,
Fluticasone 💬 		1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
92Formalin-fixed paraffin-embedded (ffpe) tissue samples analysis1件: Formaldehyde1件: Formaldehyde 💬 --1件: 98 💬
93Gastrointestinal quality OF life index----1件: 98 💬
94Height measurement----1件: 98 💬
95High dose budesonide suspension----1件: 98 💬
96High dose budesonide tablet----1件: 98 💬
97HIGH-resolution manometry----1件: 98 💬
98Honey1件: Honey1件: Honey 💬 --3件: 57, 98, 230 💬
99Humanised IGG1K monoclonal antibody against KIT----1件: 98 💬
100Infliximab1件: Infliximab1件: Infliximab 💬 1件: TNF 💬 66件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬24件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 164, 269, 270, 271 💬
101Inhaled/swallowed budesonide----1件: 98 💬
102Intraluminal impedance----1件: 98 💬
103IRL201104----1件: 98 💬
104Jorveza1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
105Jorveza 0.5 MG compresse orodispersibili1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
106Jorveza 0.5 MG orodispersible tablets1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
107Jorveza 1 MG compresse orodispersibili1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
108Jorveza 1 MG orodispersible tablets1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
109Lirentelimab1件: Lirentelimab1件: Lirentelimab 💬 --1件: 98 💬
110Loratadine1件: Loratadine1件: Loratadine 💬 1件: HRH1 💬 4件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction 💬5件: 13, 19, 46, 89, 98 💬
111Losartan potassium1件: Losartan2件: Losartan potassium ,
Losartan 💬 		1件: AGTR1 💬 17件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬5件: 36, 98, 167, 179, 215 💬
112LOW dose budesonide tablet----1件: 98 💬
113MEDI-563----5件: 44, 45, 98, 162, 299 💬
114MEDI99291件: Tezepelumab1件: Tezepelumab 💬 1件: TSLP 💬 2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬1件: 98 💬
115Medication compliance phone call----1件: 98 💬
116Mepolizumab1件: Mepolizumab1件: Mepolizumab 💬 1件: IL5 💬 13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬4件: 44, 45, 98, 162 💬
117Mepolizumab 100 MG1件: Mepolizumab1件: Mepolizumab 💬 1件: IL5 💬 13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬1件: 98 💬
118Mepolizumab 300 MG1件: Mepolizumab1件: Mepolizumab 💬 1件: IL5 💬 13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬1件: 98 💬
119Mesalamine oral product1件: Mesalazine1件: Mesalamine 💬 --1件: 98 💬
120Mometasone furoate2件: Mometasone,
Mometasone furoate		3件: Mometasone furoate ,
Mometasone furoate hydrate ,
Mometasone 💬 		1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬2件: 98, 162 💬
121Montelukast1件: Montelukast2件: Montelukast sodium ,
Montelukast 💬 		1件: CYSLTR1 💬 2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬9件: 6, 13, 19, 46, 61, 63, 85, 98, 228 💬
122Montelukast/ singulair1件: Montelukast2件: Montelukast sodium ,
Montelukast 💬 		1件: CYSLTR1 💬 2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬1件: 98 💬
123Nasonex----1件: 98 💬
124NDX-3315 and NDX-33241件: NDX-3315---1件: 98 💬
125Niox mino® airway inflammation monitor----1件: 98 💬
126OC000459----1件: 98 💬
127Omalizumab1件: Omalizumab1件: Omalizumab 💬 1件: FCER1A 💬 4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬7件: 46, 53, 65, 98, 162, 226, 299 💬
128Omeprazole1件: Omeprazole3件: Omeprazole ,
Omeprazole sodium ,
Omeprazole magnesium 💬 		2件: ATP4A,
ATP4B 💬 		3件: Collecting duct acid secretion, Gastric acid secretion, Oxidative phosphorylation 💬12件: 6, 13, 21, 46, 85, 90, 96, 97, 98, 271, 282, 298 💬
129Omeprazole 20 MG oral tablet1件: Omeprazole3件: Omeprazole ,
Omeprazole sodium ,
Omeprazole magnesium 💬 		2件: ATP4A,
ATP4B 💬 		3件: Collecting duct acid secretion, Gastric acid secretion, Oxidative phosphorylation 💬1件: 98 💬
130Omeprazole 20MG BID1件: Omeprazole3件: Omeprazole ,
Omeprazole sodium ,
Omeprazole magnesium 💬 		2件: ATP4A,
ATP4B 💬 		3件: Collecting duct acid secretion, Gastric acid secretion, Oxidative phosphorylation 💬1件: 98 💬
131Ondansetron1件: Ondansetron2件: Ondansetron ,
Ondansetron hydrochloride hydrate 💬 		5件: HTR3,
HTR3,
HTR3,
HTR3,
HTR3 💬 		3件: Neuroactive ligand signaling, Serotonergic synapse, Taste transduction 💬3件: 98, 107, 231 💬
132Oral budesonide----2件: 97, 98 💬
133Oral cromolyn sodium----1件: 98 💬
134Oral nitric oxide testing----1件: 98 💬
135Oral viscous budesonide1件: Budesonide1件: Budesonide 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
136Physical examination and questionnaires----1件: 98 💬
137Planar images----1件: 98 💬
138Propofol1件: Propofol1件: Propofol 💬 16件: GABRA,
GABRA,
GABRA,
GABRA,
GABRA,
GABRA,
GABRB,
GABRB,
GABRB,
GABRD,
GABRE,
GABRG,
GABRG,
GABRG,
GABRP,
GABRQ 💬 		8件: GABAergic synapse, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬10件: 3, 6, 21, 22, 34, 46, 70, 97, 98, 296 💬
139QAX576----4件: 51, 85, 96, 98 💬
140Reslizumab1件: Reslizumab1件: Reslizumab 💬 1件: IL5 💬 13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬2件: 44, 98 💬
141Retrospective evaluation OF endoscopy prior TO study drug----1件: 98 💬
142RPC4046----1件: 98 💬
143Saline1件: Sodium chloride1件: Sodium chloride 💬 --19件: 2, 6, 13, 17, 18, 46, 53, 67, 77, 86, 96, 97, 98, 168, 256, 271, 274, 299, 301 💬
144SB-240563----3件: 44, 45, 98 💬
145SCH55700----1件: 98 💬
146Serum biomarkers----1件: 98 💬
147Sevoflurane1件: Sevoflurane1件: Sevoflurane 💬 --8件: 6, 21, 22, 34, 70, 98, 225, 296 💬
148Single photon emission computed tomography scans----1件: 98 💬
149Sirolimus1件: Sirolimus1件: Sirolimus 💬 1件: MTOR 💬 49件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬39件: 6, 13, 15, 19, 21, 34, 35, 36, 46, 48, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 97, 98, 137, 157, 158, 192, 222, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
150SIX-foods elimination diet----1件: 98 💬
151Solrikitug high dose1件: Solrikitug1件: Solrikitug 💬 1件: TSLPR 💬 2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬1件: 98 💬
152Solrikitug LOW dose1件: Solrikitug1件: Solrikitug 💬 1件: TSLPR 💬 2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬1件: 98 💬
153Solrikitug MID dose1件: Solrikitug1件: Solrikitug 💬 1件: TSLPR 💬 2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬1件: 98 💬
154Steroid and proton pump inhibitor therapy----1件: 98 💬
155Stool sampling----1件: 98 💬
156Sucralfate1件: Sucralfate1件: Sucralfate 💬 --1件: 98 💬
157Swallowed fluticasone----1件: 98 💬
158Symptom survey----1件: 98 💬
159Technetium TC 99M1件: Technetium Tc-99m---1件: 98 💬
160Tezepelumab1件: Tezepelumab1件: Tezepelumab 💬 1件: TSLP 💬 2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬3件: 44, 45, 98 💬
161Tezepelumab apfs1件: Tezepelumab1件: Tezepelumab 💬 1件: TSLP 💬 2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬1件: 98 💬
162Tezepelumab VIA apfs1件: Tezepelumab1件: Tezepelumab 💬 1件: TSLP 💬 2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬1件: 98 💬
163Treat with lansoprazole 30 MG BID FOR 2 weeks, endoscopic examination with esophageal biopsy FOR patients with persistent symptoms----1件: 98 💬
164Unstimulated saliva sampling----1件: 98 💬
165Urine sampling----1件: 98 💬
166Viaskin milk 500 MCG----1件: 98 💬
167Viscous/swallowed budesonide----1件: 98 💬
168Vitamin D measurement1件: Vitamin D---1件: 98 💬
169Vonoprazan1件: Vonoprazan1件: Vonoprazan 💬 2件: ATP4A,
ATP4B 💬 		3件: Collecting duct acid secretion, Gastric acid secretion, Oxidative phosphorylation 💬3件: 63, 97, 98 💬
170Xanthan GUM1件: Xanthan gum1件: Xanthan gum 💬 --1件: 98 💬
171Zofran - NO intubation----1件: 98 💬